Cristian Petre Moldovan
2015, International Journal of Cancer
visibility
…
description
7 pages
link
1 file
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
Cristian Petre Moldovan
Oncotarget, 2016
View PDFchevron_right
Genomic profile of advanced breast cancer in circulating tumour DNA
Andrew M Wardley
Nature Communications, 2021
View PDFchevron_right
Aromatase inhibitors in breast cancer
Manisha Kotadiya, jaydeep savaliya
The American Journal of Geriatric Pharmacotherapy, 2004
View PDFchevron_right
Whole-genome analysis informs breast cancer response to aromatase inhibition
Craig Allred
Nature, 2012
View PDFchevron_right
Genomic assays in breast cancer: Issues yet to settle?
M. Basade
International Journal of Molecular and Immuno Oncology
View PDFchevron_right
Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis
Sudeepto Saha
2022
View PDFchevron_right
Breast Cancer Gene Research and Medical Practices
Andrea zur Nieden
View PDFchevron_right
New concepts in breast cancer genomics and genetics
Rodrigo Goncalves
Breast Cancer Research, 2014
View PDFchevron_right
Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
Pilar Eroles
Molecular Cancer Therapeutics, 2014
View PDFchevron_right
Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients
Erik H Van Beers
Clinical Cancer Research, 2010
View PDFchevron_right
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.
Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor-Positive Tumors of Tamoxifen-Treated Breast Cancer Patients
Kirsten Nielsen
Clinical Cancer Research, 2007
View PDFchevron_right
Figuring Molecular Relapse in Breast Cancer Medicine
Sophie Day
Figure, 2022
View PDFchevron_right
Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays
luis raez
JAMA Oncology, 2018
View PDFchevron_right
A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer
Christina Curtis
Molecular Oncology, 2014
View PDFchevron_right
Biochemical and Molecular Markers in Breast Cancer Patients
Mohammad J Al-Jassani
Annals of Tropical Medicine and Public Health, 2019
View PDFchevron_right
Molecular profiling of patient-derived breast cancer xenografts
Carlo Lucchesi
Breast Cancer Research, 2012
View PDFchevron_right
DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients
Teri Oldaker
Breast Cancer Research and Treatment, 1993
View PDFchevron_right
Data from Aromatase Expression Predicts Survival in Women with Early-Stage Non–Small Cell Lung Cancer
Yahya Elshimali
2023
View PDFchevron_right
Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer
Sara Bravaccini
Oncotarget, 2017
View PDFchevron_right
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer
Anita Kessels
Breast Cancer Research and Treatment, 2010
View PDFchevron_right
What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?
Ricardo Caponero
Annals of Oncology, 2009
View PDFchevron_right
Toward precision medicine of breast cancer
Jack A Tuszynski
Theoretical Biology and Medical Modelling, 2016
View PDFchevron_right
Plasma cell-free DNA in ovarian cancer
Farideh Bischoff
Cancer, 2010
View PDFchevron_right
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer
Tianhong Li
Annals of Oncology, 2017
View PDFchevron_right
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
José Cotrina
JAMA, 2011
View PDFchevron_right
Clinical and molecular aspects of breast cancer: Targets and therapies
Glauber Leitao
Biomedicine & Pharmacotherapy, 2018
View PDFchevron_right
Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen
John Martens
Oncotarget, 2014
View PDFchevron_right
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors
joseph son
PloS one, 2024
View PDFchevron_right
The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine
John Martens
Drug Discovery Today, 2008
View PDFchevron_right
Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer
Lance Liotta
Cancer research, 1995
View PDFchevron_right
Data from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Zsuzsanna Bago-horvath
2023
View PDFchevron_right
Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features
Kay Huebner
Breast Cancer Research and Treatment, 2010
View PDFchevron_right
9q31. 2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium
E. Khusnutdinova
2012
View PDFchevron_right
Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay
Conan Li
Oncotarget, 2024
View PDFchevron_right
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy
Patrizia Querzoli
Scientific reports, 2018
View PDFchevron_right
CancerBreast CancerBiologyMetastasisCancer ResearchMedicineEstrogen ReceptorInternal MedicineMutationPolymerase Chain ReactionMetastatic Breast CancerCancer Du SeinAromatase InhibitorEstrogen receptor alphaaromataseBreast NeoplasmsNeoplasm metastasisAromatase Inhibitors